Effective spatio-temporal control of transcription and replication during S-phase is paramount to maintain genomic integrity and cell survival. Deregulation of these systems can lead to conflicts between the transcription and replication machinery leading to DNA damage. BRD4, a BET bromodomain protein and known transcriptional regulator, interacts with P-TEFb to ensure efficient transcriptional elongation by stimulating phosphorylation of RNA Polymerase II (RNAPII). Here we report that disruption of BET bromodomain protein function causes DNA damage that correlates with RNAPII-dependent transcript elongation and occurs preferentially in S-phase cells.
INTRODUCTION
Maintaining the integrity of the genome throughout the cell cycle is paramount to cell survival 1 , and therefore complex systems have evolved to tackle various threats to the genome's integrity [2] [3] [4] . During S-phase, areas of chromatin that are engaged with generating RNA transcripts must be coordinated with migrating replication forks.
Disruption of either transcription or replication control and coordination can lead to the desynchronization of these chromatin-based activities, resulting in transcriptionreplication conflicts (TRCs) and subsequent replication stress, DNA damage, and cell death [5] [6] [7] [8] [9] . To avoid these collisions, these processes are separated in both time and space through the activity of several known chromatin-based complexes 3 . Specifically, the processivity of both the replication machinery and the nascent RNA strand are paramount in preventing collisions between the two 10, 11 . These systems are an active area of study, especially in cancer cells, as many amplified transcription programs and more frequent replication distinguish cancer cells from normal cells 12, 13 . The strategies that cancer cells employ to avoid TRCs are therefore of potential therapeutic interest, as the components of these TRC avoidance mechanisms could be targeted with wide therapeutic window in variety of cancers.
One source of TRCs is the aberrant formation of RNA:DNA hybrids (R-loops), caused by nascent RNA re-annealing with its DNA template strand forming a threestranded structure 3, 5, 9, [14] [15] [16] [17] [18] [19] . R-loops play various physiological roles, including Ig classswitching, CRISPR-Cas9 bacterial defense systems, and normal transcription regulation 14, [20] [21] [22] [23] [24] [25] . However, pathologic R-loops can also form from dysregulated transcription, and these pathologic R-loops can impede the progression of the transcription bubble 15 . In the case where RNAPII is stalled, the nascent RNA is allowed to re-anneal with its template strand and form a stable R-loop leading to tethering of RNAPII to the chromatin. During S-phase, these R-loop-tethered transcription bubbles create a roadblock for replication forks 26, 27 . If these roadblocks are not resolved, collisions with the replication machinery will lead to replication fork breakdown and DNA strand breaks. Important factors have been identified that prevent and resolve R-loops, including the RNAPII activator CDK9 and the RNA:DNA hybrid endonuclease RNase H1 [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
BRD4, a member of the bromodomain and extra-terminal domain (BET) protein family, is a known regulator of transcription elongation. Through its C-terminal domain (CTD) it is known to activate CDK9, the RNAPII-phosphorylating component of the positive transcription elongation factor, P-TEFb [38] [39] [40] [41] [42] [43] [44] [45] [46] . After RNAPII has initiated transcription and paused, at many genomic loci, BRD4 releases P-TEFb from its inhibitory complex and allows CDK9 to phosphorylate the second serine of the YSPTSPS repeat on the tail of RNAPII (RNAPIIpS2). Once this phosphorylation event occurs, RNAPII is able to enter the elongation phase of transcription. Consequently, inhibition of BRD4 function reduces transcription of many transcripts 38, [47] [48] [49] .
BET family inhibitors have shown activity in pre-clinical models of several cancers, and clinical trials have shown efficacy, yet mechanisms of action and predictive biomarkers remain elusive. In an effort to illuminate the role BRD4 plays in preventing cancer cell death, we have studied how the DNA damage repair systems react to BET inhibition. We see that BET inhibitors cause double strand breaks in cells undergoing S-phase replication. Furthermore, we see that overexpression of full-length BRD4 rescues the effects of BRD4 loss, but rescue fails when BRD4 is truncated to delete the P-TEFb-interacting C-terminal domain (CTD). Finally, we see that BET inhibitors cause an increase in the formation of R-loops and that overexpression of RNase H1, an endonuclease that acts on the RNA strand of R-loops, reverses BET inhibitor-induced DNA damage. These data suggest a new role for BRD4 in preventing aberrant R-loop formation and TRCs by ensuring efficient RNAPII transcription.
RESULTS

Inhibition or degradation of BET family proteins leads to spontaneous DNA damage in cancer cells
BRD4, through its two N-terminal bromodomains, interacts with the chromatin by binding to acetylated histones 50 . In previous work, we have described how a low abundance isoform of BRD4 (Isoform B) mediated chromatin dynamics and DNA damage signaling in the presence of radiation 51 . However, small molecule BET bromodomain protein inhibitors are effective against cancer cells in the absence of radiation [52] [53] [54] [55] . Several groups have reported variable effects of BET bromodomain inhibitors on DNA damage signaling [56] [57] [58] [59] [60] . We therefore sought to understand the DNA damage consequences of BET bromodomain inhibition. JQ1, a small molecule inhibitor of BET family proteins, binds to the bromodomains and competitively prevents BRD4 from interacting with chromatin 49 . In order to test whether JQ1 was able to induce a DNA damage response, we treated HeLa and HCT-116 cells with high dose (500 nM) JQ1 for 16 hours and stained for foci, a marker of DNA damage 61 . Surprisingly,
in contrast to what we and others observed in U2OS cells treated with low dose JQ1, we saw that JQ1 was able to induce foci formation, indicating that BET proteins can prevent spontaneous DNA damage ( Fig. 1a, b, Supplementary Fig. 1A and Supplementary Fig. 1B) .
Recently, a small molecule, dBET6, has been shown to cause rapid degradation of BET proteins 38 . dBET6, as with other PROTAC molecules, links JQ1 to an E3-ligase recruiter which causes ubiquitination and subsequent, rapid degradation of BET proteins. Advantages of dBET6 are that it allows for the visualization of BET protein loss and acts as a more potent BET protein inhibitor with fast time kinetics. We observed that dBET6 elicited a robust DNA damage response detectable by Western blot in HeLa cells at 100 nM concentration in as few as 6 hours. Concurrent with dBET6-induced loss of BET proteins, we observed a reduction in RNA Polymerase II phospho-Serine 2 and saw signaling both by western blot and immunofluorescence (Figure 1c, d, and   e ). These observations confirmed that loss of BET proteins result in increased DNA damage signaling.
While is a general marker for DNA damage signaling, we wanted to establish whether BET protein loss also leads to an increase in physical DNA damage such as double strand breaks. We therefore employed single cell electrophoresis (comet assay) to measure the amount of DNA double strand breaks after dBET6 treatment. Interestingly, we found that in addition to the DNA damage signaling increase, dBET6 increased the number of DNA double strand breaks (Figure 1f and g) .
These observations indicate that loss of the BET family of proteins can cause physical DNA damage as well as a robust DNA damage response.
BET protein loss induces DNA damage during S-phase
Transcription-replication conflicts, by definition, occur while the cell is actively replicating its genome during S-phase. An active replication fork, when it collides with a transcription bubble in the head-on orientation, leads to fork stalling, DNA damage, and cell death 17 . While probing for DNA damage following BET protein loss, in immunofluorescence microscopy studies, we noticed heterogeneity in which cells would display foci following dBET6 exposure. Prior work from other groups showed that BRD4 loss leads to a loss of S-phase cells 62 . While this has been described as a G1/S phase arrest, we decided to determine whether actively replicating S-phase cells could be prone to DNA damage after BRD4 loss.
To test whether BET protein loss leads to DNA damage preferentially in actively replicating cells, we labeled HeLa cells with EdU to monitor actively replicating cells while simultaneously treating with BET6 for two hours. Our hypothesis was that, if BET protein loss is leading to TRCs, that S-phase cells that are actively replicating would preferentially exhibit a DNA damage response. Accordingly, we observed that foci formed only in the cells that were labeled with EdU by immunofluorescence ( Fig. 2a and b). We also labeled OCI-AML2 cells, another JQ1 sensitive cell line 63, 64 , and also saw that EdU positive cells showed the most DNA damage following dBET6 treatment (Supplementary Fig. 2A and Supplementary Fig. 2B ). These data indicate that BET protein loss is specifically leading to DNA damage in cells that are actively replicating in S-phase.
To determine whether this S-phase-specific DNA damage was resulting in a loss of cells in S-phase, we analyzed the cell cycle of HeLa cells treated with JQ1 or dBET6.
As shown in Fig. 2c , we saw that both JQ1 and dBET6 led to a decreased proportion of cells in S-phase, suggesting that BET protein loss leads loss of replicating cells.
The observation that BET protein loss was causing DNA damage in S-phase led us to suspect that BET inhibitor-treated cells were under replication stress. To test this, we measured phosphorylation of RPA2, a downstream target of the replication stress master kinase ATR. RPA2 is known to be phosphorylated on Serine 33 (RPA2-pS33) by ATR in response to replication stress 65 . BET inhibition with dBET6 caused a robust increase in RPA2-pS33 (Figure 2d ), indicating that BET inhibition causes replication stress, and providing further evidence that BET protein loss leads to TRCs.
The C-Terminal Domain of BRD4 is necessary to prevent DNA damage caused by
BET protein loss
The BET protein family consists of four members: BRD2, BRD3, BRD4, and BRDT, (of note, BRDT is expressed mainly in the testes) 66 . Inhibitors of this family of proteins, namely JQ1 and the degrader dBET6, function by binding to the bromodomains which are shared by all members. Thus, it is important to elucidate which member is responsible for the DNA damage seen by dBET6 treatment. To test this, we used siRNA to knock down BRD2, BRD3, and BRD4 and measured signaling ( Fig. 3a and Supplementary Fig. 3A ). After 72 hours of knock down, we wealth of studies that established mechanisms of BRD4 in transcription regulation, and earlier work showing replication dysfunction caused by BRD4 loss 30, 38, 67, 68 , we focused on the role of BRD4 in the prevention of TRC-induced DNA damage.
The full-length isoform of BRD4, isoform A, contains several known domains,
including two bromodomains, an extra-terminal domain, and a C-terminal domain (Fig.   3b ). The two bromodomains, which bind to acetylated lysine on histone tails, and the extra-terminal domain are shared among all BET protein members. The C-terminal domain, however, is unique to BRD4 isoform A and interacts with the P-TEFb complex that contains CDK9, leading to Serine 2 phosphorylation of RNAPII and transcription pause-release [38] [39] [40] [41] [42] [43] [44] [45] [46] . Also, previous work showed that CDK9 inhibition leads to an increase in R-loop-induced stalled RNAPII and potentially TRCs 20, 69 . Thus, we hypothesized that BRD4 loss could also lead to CDK9 dysfunction, resulting in TRCs and DNA damage. Moreover, we reasoned that the P-TEFb-interacting CTD would be required to prevent TRCs and DNA damage.
To determine the role of BRD4 in preventing damage caused by BET protein loss, we developed a panel of inducible BRD4 overexpression constructs in order to test their ability to rescue the effects of dBET6 (Fig. 3b) . The panel included two naturally occurring isoforms, A and C. Isoform A being the full length isoform mentioned above, and isoform C as a shorter isoform only including the two bromodomains and the extraterminal domain 56 (and lacking the CTD). We also developed a truncated construct of isoform A missing only the CTD (A CTD) which has previously shown to interact with CDK9 68 . Finally, we developed a construct excluding the extra-terminal domain (C ET).
These constructs were used to develop stable cell lines under doxycycline control to overexpress the BRD4 isoforms ( Supplementary Fig. 3B ).
In order to determine whether BRD4 isoform A (full length isoform) was able to rescue the DNA damage effects caused by dBET6, we induced isoform A expression with doxycycline for 24 hours before treatment with dBET6. We found that isoform A was indeed able to rescue the signaling caused by dBET6 ( Fig. 3c, d , and Supplementary Fig. 3C ). While, we saw that isoform A was able to rescue the effects of dBET6 treatment, the protein levels of overexpression construct remaining after dBET6 treatment were difficult to detect by Western blot. To further verify rescue of TRC-induced DNA damage by BRD4 isoform A, we measured BRD4 levels by immunofluorescence staining of dBET6-treated cells that either did, or did not, contain the overexpression construct ( Supplementary Fig. 3D ). As expected, isoform A was still present after dBET6 treatment only in cells expressing the induced rescue construct, confirming that the rescue o
We also observed that isoform A was able to rescue the loss of RNAPIIpS2, indicating that overexpressing full-length BRD4 was able to ensure efficient transcription elongation even in the presence of dBET6. These data suggest that BRD4 is sufficient in rescuing the effects of dBET6. Next, we applied the same conditions to the entire panel of BRD4 overexpression constructs by western blot (Fig. 3c and d) . Importantly, none of the other overexpression constructs was able to rescue either the signaling or the loss of RNAPIIpS2. Furthermore, we saw that only isoform A was able to rescue the S-phase specific foci caused by dBET6 treatment (Fig. 3e and f) .
These observations indicate that the C-terminal domain (CTD) is required to prevent BET inhibitor-induced loss of RNAPIIpS2, TRC, and DNA damage.
Next, we wanted to elucidate whether the CTD of BRD4 was necessary to rescue the DNA double strand breaks caused by dBET6 treatment. To test this, we used a comet assay to quantify the breaks following dBET6 treatment following overexpression of isoform A or A rescue the dBET6-induced DNA double strand breaks. This further indicates that the Cterminal domain of BRD4 is necessary to prevent spontaneous TRCs and subsequent DNA double strand breaks.
BET inhibition leads to an increase in R-loop-dependent DNA damage
R-loops have been previously shown to cause transcription-replication conflicts and replication stress in cancer 3, 5, 9, [14] [15] [16] [17] [18] [19] . Specifically, an R-loop is able to tether a stalled RNAPII to the chromatin upon which becomes a roadblock for replication machinery.
RNAPII, after initiation of transcription of ~50 bp, becomes paused until a second phosphorylation event of the second serine on its tail. BRD4, through its C-terminal domain, activates CDK9 to undergo this phosphorylation event and ensure efficient transcription elongation 40, 41, 43, 46, 68, 70 . Previous work has also shown that loss of BRD4 leads to decreased traveling ratios of RNAPII after dBET6 treatment, indicating that RNAPII is stalled on the chromatin 38 . Furthermore, previous studies have indicated that direct chemical inhibition of CDK9 leads to stalled RNAPII and an increase in R-loop formation 21, 28 . Therefore, we hypothesized that loss of BRD4 may also lead to an increase of R-loops, and that those R-loops are responsible for the TRCs seen after BRD4 loss.
To determine whether BRD4 loss leads to an increase in R-loop formation, we employed the R-ChIP-seq technique which has previously been described as a way to view R-loop formation on the chromatin 69 . R-ChIP employs the use of a catalytically inactive form of the R-loop-specific endonuclease, RNase H1. The mutation, D210N, allows RNase H1 to bind to, but not resolve, R-loops. The construct is tagged with a V5 peptide, which then allows it to be enriched from crosslinked cells, along with associated chromatin, for ChIP-sequencing ( Supplementary Fig. 4A ). We performed R-ChIP-seq in dBET6-exposed cells and found dramatic increases in global R-loop formation (Fig. 4a) . Similarly, we saw globally-increased ChIP signal in dBET6treated cells. Furthermore, we validated three previously described 42 BRD4 occupying loci using R-ChIP-qPCR ( Fig. 4b and c) . Surprisingly, while we saw most of the R-loop formation near the promoter regions, there was also increased R-loop formation throughout the length of the gene. In addition, we also saw a decrease of RNAPIIpS2 along the length of these loci as well ( Supplementary Fig. 4B ). This indicates that BRD4 not only prevents pause-release of RNAPII, but also prevents the accumulation of R-loops and RNAPII stalling throughout the length of the gene.
We next postulated that the R-loops formed by BRD4 loss would be the cause of the TRCs, replication stress, and DNA damage. To elucidate this, we employed the overexpression of V5-tagged wild-type RNase H1, which is known to be able to resolve R-loops and reverse DNA damage caused by their existence 27 . As a negative control, we used a V5-tagged RNase H1 mutant, containing mutations at W43A, K59A, K60A
and D210N (WKKD), which has been previously described to lack both the catalytic activity as well as the DNA binding activity of RNase H1 28 . To test whether RNase H1 was able to rescue the TRCs caused by BRD4 loss, we overexpressed either the WT RNase H1 or the WKKD mutant construct, treated with dBET6, and stained for V5, EdU, and ( Fig. 4d, e, and Supplementary Fig. 4C ). Consistent with our hypothesis that BET inhibition leads to TRC and DNA damage via increased formation of R-loops, over-expression of WT RNaseH1, but not the non-binding WKKD mutant, rescued the DNA damage induced by BRD4 loss in EdU positive cells. We then sought to test whether RNase H1 was able to rescue the DNA double strand breaks caused by dBET6 ( Fig. 4f and g) . We observed that RNase H1 was also able to rescue these DNA double strand breaks. These data indicate that following BRD4 loss, R-loops are formed and lead to TRCs and subsequent DNA damage.
Finally, because BRD4 plays a role in transcription, we sought to understand whether BRD4 was playing a direct role in preventing R-loop formation, or whether it was indirectly preventing R-loop formation through the transcriptional control of other proteins implicated in Rshown to be involved with R-loop processing 71, 72 . We saw that dBET6 treatment did not n the R-loopdependent TRCs and DNA damage occurred (Fig. 4h ).
Active transcription and RNAPII occupancy are required for BET protein-loss induced damage
There are five stages of transcription: RNAPII recruitment, initiation, pause/release, elongation, and termination 73, 74 . Transcription initiation is denoted by a phosphorylation event, namely that CDK7, a subunit of TFIIH, phosphorylates Serine-5 on the tail of RNAPII 75 . After ~50bp of nascent transcription, RNAPII undergoes a pausing event until CDK9, a subunit of P-TEFb, phosphorylates Serine-2 on the tail of RNAPII 76 . Inhibitors of these two kinases exist and have been shown to have different effects on RNAPII occupation of chromatin 21 . Triptolide (TRP) inhibits CDK7 and results in the blocking of transcription initiation and leads to the degradation of RNAPII ( Supplementary Fig. 5A ). DRB inhibits CDK9 and leads loss of RNAPIIpS2 and stalling of RNAPII on the chromatin, resulting in R-loops and TRCs 28,77 ( Supplementary   Fig. 5B ). With this understanding, we hypothesized that these two molecules would have differing effects on the DNA damage caused by BRD4 loss.
To test whether degradation of RNAPII with TRP would be able to rescue the DNA damage effects of dBET6 treatment, we designed an experiment to pre-treat and manipulate RNAPII prior to dBET6 exposure, as described in Figure 5a . After pretreating with either TRP or DRB, we washed out the drugs and treated with dBET6 for one hour. Following the dBET6 treatment, cells were fixed and stained for ( Fig.   5b and c) . Remarkably, we saw that TRP was able to rescue the DNA damage effects of dBET6, while DRB was not. We also co-treated TRP and dBET6 in HCT-116 cells and also saw that TRP was able to rescue the DNA damage effects caused by dBET6
( Supplementary Fig. 5C and Supplementary Fig. 5D ). These data indicate that RNAPII occupation on the chromatin is necessary for DNA damage caused by BRD4
loss.
Finally, we wanted to explore the correlation between RNAPIIpS2 and DNA damage caused by dBET6 treatment. We observe that when BRD4 isoform A is overexpressed, there is an increase in RNAPIIpS2 (Fig. 5d ). In addition, we see that
RNAPIIpS2 negatively correlates with following dBET6 treatment both in HeLa cells and HEK-293T cells (Fig. 5e, f, Supplementary Fig. 5E, Supplementary Fig.   5F ). These data again suggest that the loss of BRD4 leads to loss of transcription and stalling of RNAPII on the chromatin leading to TRCs and subsequent DNA damage.
DISCUSSION
Inhibitors of BRD4 have been shown to be effective treatments for several
cancers, yet the mechanism of action remains unclear [52] [53] [54] [55] . Specifically, questions remain as to why inhibition of BRD4, which controls global transcription 38 , may preferentially impact cancer cells more than normal cells -a feature that is required of all effective chemotherapies. Here, we propose a novel role for BRD4 in the prevention of R-loops, transcription-replication conflicts, and DNA damage ( Figure 6 ).
Our data show that inhibition or degradation of BET proteins, with JQ1 or dBET6 respectively, leads to an accumulation of DNA damage signaling and DNA double strand breaks. When we began to characterize the nature of the DNA damage, we also noticed that the cell cycle state dictated whether or not they accumulated this damage.
Specifically, we saw that the damage was S-phase specific. Due to our data and the literature showing that BET proteins play a role in transcription, we postulated that the S-phase dependent DNA damage caused by BET protein loss could be working through a mechanism of increased transcription-replication conflicts.
Due to the fact that BET protein inhibitors such as JQ1 and degraders such as dBET6 target the bromodomains of BRD2, BRD3, and BRD4, it is unclear if one member of the family is responsible for the DNA damage caused by BET protein loss.
Several works have shown unique properties of each [78] [79] [80] , they also share some redundant functions. Our data show that while both BRD2 and BRD4 show increased signaling after 72 hours, we saw that overexpression of the full-length isoform (isoform A) was able to effectively rescue the DNA damage effects of BET protein degradation by treatment with dBET6. Furthermore, we observed that the C-terminal domain of BRD4 was necessary to rescue this effect.
Our data and the literature show that the C-terminal domain plays a critical role in the activation of RNAPII to ensure efficient elongation [38] [39] [40] [41] [42] [43] [44] [45] [46] . BRD4, through its C-terminal domain, interacts with CDK9 to phosphorylate Serine-2 on the heptapeptide repeat on the tail of RNAPII. This phosphorylation event allows RNAPII to proceed with transcription elongation on schedule. Our data is in line with other studies that show that inhibition of either BRD4 or CDK9 leads to R-loop formation on the chromatin 28 . R-loops then are able to tether RNAPII to the chromatin and increase the likelihood of collisions with the replication machinery during S-phase.
In recent years, the importance of R-loops has become more apparent. While they play critical roles normal physiological activity 14, [20] [21] [22] [23] [24] [25] , it has also come to light that aberrant R-loops can lead to transcription-replication conflicts, DNA damage, and cell death 3, 5, 9, [14] [15] [16] [17] [18] [19] . Our data show that BRD4 loss leads to an increase in R-loop formation on the chromatin, and the damage seen following BRD4 loss can be rescued by overexpressing RNase H1, an endonuclease that resolves R-loops. These observations indicate that BRD4 is important to cancer cells in that ensuring efficient transcription during S-phase prevents R-loop dependent conflicts between transcription and replication. We believe this is an important observation because cancer cells are generally replicating and transcribing more than normal cells, thus may be more dependent on BRD4 to prevent the transcription and replication machinery from colliding. This finding might also shed light on additional prior studies. Early work on BRD4 knockout mice showed both embryonic lethality and replication deficits 67, 81 .
Additionally, studies of the normal tissue toxicities of whole-animal knockout of BRD4 could indicate vulnerability in rapidly replicating normal tissues 82 . One outstanding question that remains to be completely resolved is what makes a cancer cell more or less sensitive to BRD4 loss. It has been shown that certain cancer cell lines are more sensitive to BET protein inhibition 52 , yet it is unclear as to why this is the case. For example, our group and others have shown that BRD4 loss in U2-OS cells does not result in an increase in signaling 56, 59 . Notably, it is reported that that U2-OS cells do not exhibit a decrease in RNAPIIpS2 following BRD4 loss 59 . As is well known, different cells operate under different transcriptional programming. We hypothesize that certain cancer cell lines may be more globally dependent on BRD4-mediated transcriptional activation, leading to R-loops, TRC and DNA damage upon BET inhibition. Specifically, we hypothesize that RNAPIIpS2 loss after BRD4 degradation could be predictive of whether a cancer cell line exhibits DNA damage following treatment. Through further study of both BRD4 and the role of R-loops in cancer, we hope that we can identify new chemotherapeutic targets and broaden the effectiveness of BET inhibitors in cancer therapies. ChIP-qPCR signal for RNAPIIpS2 following treatment of HeLa cells with DMSO or dBET6 for 2 hours at loci described in Fig. 3b and c. C. Western blot image confirming validation of wild-type or WKKD mutant RNaseH1-V5 constructs. Source data are provided as a Source Data file.
Figure S5: RNAPII loss rescues TRCs caused by BET inhibition
A. Western blot images of HeLa cells treated with DMSO or decreasing levels of triptolide for four hours: lysates probed for the epitope as described beside each panel.
B. Western blot images of HeLa cells treated with DMSO or decreasing levels of DRB
for four hours: lysates probed for the epitope as described beside each panel. C.
Representative images and D. quantification of western blot images of HCT-116 cells treated with DMSO, 1 μM triptolide, and/or 100 nM dBET6 as described for four hours before harvest: lysates probed for the epitope described beside each panel. E.
Representative images and F. quantification of western blots of HeLa cells treated with 100 nM dBET6 for indicated times: lysates probed for the epitope described next to each panel. ANOVA was performed on D.. Data represent the mean ±SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Source data are provided as a Source Data file.
(1:500IF, A21428, Invitrogen); Goat Anti-Rabbit IgG Alexa Fluor 488nm (1:500IF, A11008, Life Technologies).
DAPI (1:2000IF, Thermo Fisher Scientific) was used to stain nuclei. SYBR Gold assay. Propidium Iodide (50 μg/mL, VWR) was used to stain nuclei for cell cycle analysis.
Immunofluorescence
Cells were grown on coverslips or in micro-chamber wells (Ibidi) overnight before induction or treatment. When the experiment was completed, cells were washed with ice cold PBS and fixed with 4% paraformaldehyde for 20 minutes at room temperature (RT). After fixation, cells were washed with PBS and then blocked in 5% goat serum and .25% Triton-, rocking. Following blocking, primary antibodies were diluted in the same blocking buffer and incubated at 4°C overnight, rocking.
Following incubation with primary antibody, cells were washed three times with PBS and stained with the appropriate secondary antibody diluted and DAPI in blocking buffer at RT for 1 hour, rocking. After incubation with secondary antibody, cells were washed three times with PBS. In the case of cells grown on coverslips, cells were mounted on slides using Prolong Gold (Thermo Fisher Scientific) before imaging. Cells grown in micro-chamber wells were left in PBS before immediate imaging. Immunofluorescence objective.
CellProfiler. All images within a single experiment were fed into the same pipeline and speckles (foci) were counted in an unbiased fashion using the automated program.
integrated intensity of the foci within that nucleus.
Western Blotting
Whole cell lysates were prepared with a whole cell lysis buffer ( 
Single Cell Electrophoresis (Comet) Assay
Plasmid Construction
The iBRD4 plasmids were constructed using the pCW57-GFP-2A-MCS backbone (Addgene, 71783), which was a gift from Adam Karpf and previously described 83 .
Gibson assembly was used to insert either mCherry-2A-Flag-BRD4 isoform A or isoform C into the backbone in place of the TurboGFP-P2A-hPGK promoter-PuroR-T2A-rTetR
region. The Cextrasequencing was performed to verify the cloning products.
Small Molecule Inhibitors
The BET protein degrader dBET6 was a gift from Nathanael Gray and previously described 38 . dBET6 was used at a concentration of 100 nM in all experiments except those involving the iBRD4 system, in which it was used at 10 nM. The BET protein inhibitor JQ1 was a gift from James Bradner and previously described 84 
EdU Detection
EdU detection was done according using the EdU-Click Chemistry 488 kit (Sigma-Aldrich, BCK-EDU488) according to manufacturer's instructions. In brief, cells were pulsed with 10 μM EdU alongside simultaneous treatment with DMSO or dBET6. Cells were then fixed, washed with PBS, and blocked as described above. Cells were then incubated at RT for 30 minutes in the click chemistry cocktail. Following incubation, cells were washed three times with PBS. After the click chemistry was completed, cells were further process according to the immunofluorescence methods described above.
Flow Cytometry and Cell Cycle Analysis
For cell cycle analysis, cells were trypsinized and washed with ice cold PBS. TSS  E1  I1  E2  I2  E3  I3  E4  TSS  E1  I1  E2  I2  E3  I3  E4  TTS  TSS  E1  I1  E2 TSS  E1  I1  E2  I2  E3  I3  E4  TSS  E1  I1  E2  I2  E3  I3  E4  TTS  TSS  E1  I1  E2  I2   % Input   RPL30  SRSF1  SRSF2 HeLa, ChIP-qPCR, 2hr 100nM dBET6, Anti-RNAPIIpS2 
